Publicação
Improving health outcomes through treatment sequencing optimization in multiple myeloma: a simulation model in transplant‐ineligible patients
| dc.contributor.author | Geraldes, C. | |
| dc.contributor.author | Neves, M. | |
| dc.contributor.author | Bergantim, R. | |
| dc.contributor.author | Silva, Catarina | |
| dc.contributor.author | Leal da Costa, F. | |
| dc.date.accessioned | 2025-04-09T14:36:21Z | |
| dc.date.available | 2025-04-09T14:36:21Z | |
| dc.date.issued | 2024 | |
| dc.description | © 2024 The Author(s). Cancer Reports published by Wiley Periodicals LLC. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. | pt_PT |
| dc.description.abstract | Objectives: Patients with multiple myeloma often require multiple treatment lines. The order in which treatments are sequenced has impact on clinical outcomes. This study aimed to estimate progression-free survival (PFS) and overall survival (OS) with common treatment sequences used in Portugal and the incremental benefit of an optimal sequence in transplant-ineligible patients with multiple myeloma. Methods: A state-transition sequential model with a five-health state conceptual structure was developed to simulate and compare survival outcomes between treatment sequences up to four lines of treatments. Data sources included randomized clinical trials and indirect treatment comparisons. A panel of Portuguese hematologists listed four most common treatment sequences and optimal sequence of choice in transplant-ineligible patients. Results: Our simulation estimated an OS between 6.1 and 7.8 years using the most common sequences, with VMP + DRd + Pd + Kd as the most effective (7.8 years). Optimal sequence of choice (DRd + PVd + Kd + Vd) achieved OS of 9.8 years and may extend OS in 2.0-3.7 years vs. most common sequences (26%-61% increase). This benefit was mostly explained by extended PFS in the first line of treatment. Conclusion: Model results demonstrate that choosing the most effective treatment upfront is crucial in delaying disease progression thus yielding better survival outcomes in transplant-ineligible patients. There was a clear survival benefit in using daratumumab-based regimens in first line. This modelling exercise highlights the need to raise awareness around the impact of sequencing strategies to improve patient's outcomes. | pt_PT |
| dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
| dc.identifier.citation | Cancer Rep (Hoboken). 2024 Oct;7(10):e70027 | pt_PT |
| dc.identifier.doi | 10.1002/cnr2.70027 | pt_PT |
| dc.identifier.eissn | 2573-8348 | |
| dc.identifier.uri | http://hdl.handle.net/10400.5/100110 | |
| dc.language.iso | eng | pt_PT |
| dc.peerreviewed | yes | pt_PT |
| dc.publisher | Wiley | pt_PT |
| dc.relation.publisherversion | https://onlinelibrary.wiley.com/journal/25738348 | pt_PT |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | pt_PT |
| dc.subject | Multiple myeloma | pt_PT |
| dc.subject | Optimization | pt_PT |
| dc.subject | Outcomes | pt_PT |
| dc.subject | Overall survival | pt_PT |
| dc.subject | Simulation | pt_PT |
| dc.subject | Treatment sequencing | pt_PT |
| dc.title | Improving health outcomes through treatment sequencing optimization in multiple myeloma: a simulation model in transplant‐ineligible patients | pt_PT |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.issue | 10 | pt_PT |
| oaire.citation.title | Cancer Reports | pt_PT |
| oaire.citation.volume | 7 | pt_PT |
| person.familyName | Silva | |
| person.givenName | Catarina | |
| person.identifier.orcid | 0009-0005-5079-1677 | |
| rcaap.rights | openAccess | pt_PT |
| rcaap.type | article | pt_PT |
| relation.isAuthorOfPublication | 0a4027de-c89a-4657-bb6e-dad64570c5f4 | |
| relation.isAuthorOfPublication.latestForDiscovery | 0a4027de-c89a-4657-bb6e-dad64570c5f4 |